Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Caroline Dutriaux et al.|The Lancet Oncology|2017Cited by 491
Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in <i>NRAS</i>-mutant cutaneous melanoma.Reinhard Dummer, Keith T. Flaherty, Dirk Schadendorf et al.|Journal of Clinical Oncology|2016Cited by 30